Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

MAP kinase pathways and calcitonin influence CD44 alternate isoform expression in prostate cancer cells

  • 1,
  • 1,
  • 1 and
  • 1Email author
BMC Cancer20088:260

https://doi.org/10.1186/1471-2407-8-260

©  Robbins et al; licensee BioMed Central Ltd. 2008

  • Received: 15 May 2008
  • Accepted: 15 September 2008
  • Published:
Open Peer Review reports

Abstract

Background

Dysregulated expression and splicing of cell adhesion marker CD44 is found in many types of cancer. In prostate cancer (PC) specifically, the standard isoform (CD44s) has been found to be downregulated compared with benign tissue whereas predominant variant isoform CD44v7-10 is upregulated. Mitogen-activated protein kinase pathways and paracrine calcitonin are two common factors linked to dysregulated expression and splicing of CD44 in cancer. Calcitonin has been found to increase proliferation and invasion in PC acting through the protein kinase A pathway.

Methods

In androgen-independent PC with known high CD44v7-10 expression, CD44 total and CD44v7-10 RNA or protein were assessed in response to exogenous and endogenous calcitonin and to inhibitors of protein kinase A, MEK, JNK, or p38 kinase. Benign cells and calcitonin receptor-negative PC cells were also tested.

Results

MEK or p38 but not JNK reduced CD44 total RNA by 40%–65% in cancer and benign cells. Inhibition of protein kinase A reduced CD44 total and v7-10 protein expression. In calcitonin receptor-positive cells only, calcitonin increased CD44 variant RNA and protein by 3 h and persisting to 48 h, apparently dependent on an uninhibited p38 pathway. Cells with constitutive CT expression showed an increase in CD44v7-10 mRNA but a decrease in CD44 total RNA.

Conclusion

The MEK pathway increases CD44 RNA, while calcitonin, acting through the protein kinase A and p38 pathway, facilitates variant splicing. These findings could be used in the formulation of therapeutic methods for PC targeting CD44 alternate splicing.

Keywords

  • Prostate Cancer
  • Calcitonin
  • CD44 Total
  • CD44 Variant
  • CD44 Transcription

Background

CD44, a transmembrane glycoprotein, is the product of a gene that can undergo extensive alternate splicing. The standard (CD44s) isoform is ubiquitous but tissue-specific isoforms may include an assortment of 10 variant (v) exons (CD44v). CD44 facilitates multiple cellular functions. CD44 enables cell-cell and cell-matrix adhesion – primarily to its main ligand hyaluronan, and links the cell membrane to the actin cytoskeleton, modulating motility. CD44 is universally dysregulated in human cancer, and this imbalance of isoforms allows tumor growth and invasion [1–8]. CD44v are expressed in prostatic secrectory cells while CD44s is found in the whole epithelium. About 30% of cases of prostate cancer (PC) undergo a transition from quiescent to aggressive. Altered CD44 and other adhesion molecules permit this transition in which tumor cells detach, interact with proteins that digest stromal matrix, migrate through matrix, and intravasate into lymphovascular channels.

By isolating RNA from clinical PC specimens, we discovered that the major variant isoform expressed in PC is CD44v7-10. This PC signature was consistently present in both primary and metastatic PC [1–3]. Interference against this CD44v caused a 69% reduction in invasion index compared to untreated control cells[3]. Moreover, PC loses the splicing ability to produce the CD44s expressed in benign prostate[3, 9, 10]. CD44 must oligomerize to bind matrix ligands or to cause metastasis[11] and variant isoforms, with longer extracellular tails, have altered ability to complex[12]. We found that the CD44v7-10 isoform makes PC cells preferentially bind to fibronectin rather than hyaluronan; re-expression of CD44s causes the predominant ligand to revert from fibronectin back to hyaluronan[4]. In mouse xenografts of PC-3 prostate tumor, forced expression of CD44s reduced growth in vitro and tumorigenicity[5], and our use of RNAi against CD44v7-10 in xenografts yielded similar effects (unpublished results).

In PC, calcitonin (CT) acts as a paracrine growth factor that up-regulates CD44 variant[4, 6]. In histologic specimens PC, but not benign secretory epithelium, contains CT[13] and its receptor (CTR)[14], and CT exerts paracrine effects that promote proliferation[15], invasion[16], and metastasis[17]. CTR, essential for prostate cancer tumorigenicity[18], is coupled to the transduction protein Gsα. We have shown that CT promotes alternate splicing leading to CD44v7-10 mRNA and protein[4, 6] by acting through Gsα signaling[3]. Gsα stimulates the cyclic AMP signaling cascade[17, 19] and protein kinase A (PKA)[16].

PKA, in turn, acts on the 3 main MAPK pathways: a growth factor-responsive pathway that uses MAP2K (also called MEK) as key downstream effector; and two stress-activated pathways, c-jun N-terminal kinase (JNK), and p38 kinase, that respond to stress including cytokines, osmotic shock, and irradiation. CD44 variants activate MAPK pathways[20], sometimes by functioning as co-receptors for growth factors[21]. MAPK pathways, in turn, can cause CD44 alternative splicing to include variant exons[22]. Oncogenes such as ras[7, 23] and mitogens using the MEK-ERK MAP kinase (MAPK) pathway[7], but not the p38 pathway[24], induce CD44 promoter activity and increase expression of certain CD44v. To test whether these influences modulate RNA levels and alternative splicing of CD44 in PC, we studied the CT signaling system, PKA, and MAPK pathways. CD44 mRNA and protein levels were measured.

Methods

Cell lines

PC-3 cells (American Type Culture Collection, Manassas, VA) were incubated in F12-K medium, 10% fetal calf serum, and antibiotics at 37°C in a 5% CO2 incubator. Gsα-QL cells, CT+, CT-, and CTR-cells were gifts of Dr. Girish Shah, Univ. of Louisiana-Monroe[17]. The Gsα-QL cells were derived from metastasizing PC-3M cells stably transfected by a plasmid that directs expression of mutant, constitutively active Gsα [17, 19]. These three cell lines were grown in RPMI 1640 with L-glutamine, 5% fetal calf serum, 15% horse serum and antibiotics. Benign BPH-1 cells (from Dr. Simon Hayward, Vanderbilt Univ., Nashville, TN) were grown in RPMI with 10% fetal calf serum and antibiotics. For each experiment, cells in a flask were trypsinized and saline washed to remove trypsin. 200,000 cells were plated per well on a 6-well plate. Cells were adherent and 80% confluent for all experiments. Each treatment was applied to three wells, with three other wells as mock treated controls.

Effect of exogenous calcitonin

PC-3M cells express both CT and CT-receptor (CTR)[16]. To test the effect of solely exogenous CT on CD44, we used the derivative, CT-minus (CT-). CT-cells have endogenous CT stably knocked down to undetectable levels using anti-CT hammerhead ribozymes[25]. Salmon CT (BAChem, Torrance, CA) was used at a physiologic 50 nM dose[14, 16], which effectively alters CD44[6], or at 250 nM. The Kd of CTR is 4–21 nM[15]. To detect acute versus long-acting effects on RNA and protein levels, cells were treated with 50 nM CT and harvested after 3 h or 48 h. To determine whether CT effects on CD44 proteins resulted from de novo protein synthesis versus protein stabilization, cycloheximide (10 nM) was given to CT-cells after 3 hr of CT exposure, and cells harvested 1 hr, 3 hr, 6 hr, and 9 hr subsequently, similar to a prior CD44 study[26]. Also tested were highly invasive, CT positive Gsα-QL cells[17]. Finally, to rule out non-CTR-mediated CT effects, two negative controls were tested: PC-3 cells (shown to be negative for CT receptor[14]), and cells called CTR-, derived from PC-3M cells after anti-CT receptor ribozyme knockdown of CTR[18]. CTR-cells have very low levels of CD44v protein[4].

Effect of endogenous calcitonin

To test the effect of endogenous CT on CD44 RNA, we used PC-3M cells expressing CT-pcDNA 3.1 plasmid (CT+), which constitutively express CT[25]. 125,000 PC-3M or CT+ cells per well were plated and allowed to grow for 72 hours.

Inhibition of protein kinase A and MAPK components

Gsα-QL cells were chosen for these studies because they have the highest baseline CD44v[3]. Protein kinase A inhibitor H-89 (in 50% ethanol) (Calbiochem, La Jolla, CA) was added to cells in fresh medium (1 mL/well) at 1 μM, previously shown effective in nerve cells[23] or at a 10 μM dose. Cells were incubated with H-89 for 24 hours[27] then harvested.

In similar assays, either 10 μl of 1 mM JNK inhibitor (SP600125, Calbiochem) or 12.5 μl of 2 mM MEK inhibitor (PD98059, Calbiochem) in water were added, yielding concentrations previously shown effective: 10 μM for JNK[28] and 25 μM for MEK (personal communication, Dr. Bolin Liu). p38 kinase inhibitor (SB203580, Calbiochem) was used at 10 μM[29, 30] in DMSO, and control cells received DMSO only. Cells were incubated for the optimum time of 48 h[28] to show effects.

Interaction of CT with MAPK pathways

Based on results above, we tested the effect of pretreatment with MEK or p38 kinase inhibitors on CT-mediated alteration of CD44 expression. 25 μM MEK inhibitor or 10 μM p38 kinase inhibitor was added to CT-cells 4 hours prior to administering 50 nM CT. Cells were harvested after 48 h as above.

Real time TaqMan RNA analysis

Total RNA was prepared from cell pellets using Trizol (Invitrogen, Carlsbad, CA) as described by the manufacturer. RNA was further purified by isopropanol precipitation, resuspended in RNAse-free water, and its concentration measured. Complementary DNA (cDNA) was synthesized from 4 μg total RNA in 20 μl reaction mixture as we did previously[9]. At least triplicate samples were run using a primer/probe set for all CD44v that brackets the entire variant region[6], one for CD44 total that binds a standard exon, and 18S ribosomal RNA. Quantitative PCR reactions were optimized to 4 μg cDNA (0.16 μg with 18S) plus the manufacturer's master mix and primer/probe sets (Applied Biosystems, Foster City, CA) in a volume of 20 μl. The amplification protocol was as follows: hold 50°C 2 min, 95°C 10 min, then 40 cycles of (95°C for 0:15 and 60°C for 1:00) using the ABI Prism 7700 cycler (Perkin-Elmer, Waltham, MA). Primer/probe sets for CD44v were: forward, AACGCTTCAGCCTACTGCAAA; reverse, TCTTCCAAGCCTTCATGTGATG; probe, GATTTGGACAGGACAGGACCTCTTTCAATG. For CD44 total we used forward, CAACTCCATCTGTGCAGCAAA; reverse, GTAACCTCCTGAAGTGCTGCTC; probe, CATATTGCTTCAATGCTTCAGCTCCACCTG. Primer and probe sets for 18S were proprietary to the manufacturer.

Western blot analysis

Cultured cells were directly lysed in their wells using RIPA buffer (Upstate Biologicals, Lake Placid, NY) with protease inhibitor Complete-mini tablet (Applied Science, Indianapolis, IN). Protein concentration of the cell lysate was estimated by Bradford method. Samples were resolved on SDS-PAGE using 25 μg sample/lane with the NuPAGE system (Invitrogen, Carlsbad, CA). 5 μl of Rainbow protein marker (RPN 756, Amersham, Piscataway, NJ) was run in at least one lane. After electrophoresis for 2 hr, the protein was transferred to PVDF. Three primary antibodies were used. To assess CD44v9 (the largest component of the overexpressed CD44v7-10) the membrane was reacted with neat supernatant from the hybridoma cell line HB-258 (ATCC). CD44 standard was assessed using anti-HCAM (DF1485, Santa Cruz Biologicals, Santa Cruz, CA, 1:2000), which binds all CD44 isoforms. Anti-β-actin antibody (Sigma, St. Louis) was used at a dilution of 1:10,000. Membranes were washed 3 × 15 min in TBS with 20 mM Tris pH 7.5 and 1:1000 dilution of goat anti-mouse IgG antibody labeled with biotin (Bio-Rad) was added at 1:9000 dilution in 5% skim milk for 1 hr. Reactivity was detected using a chemiluminescent system (SuperSignal West Pico Substrate, Pierce Biotechnology, Rockford, IL). Each experimental run was conducted at least twice.

Statistical analysis

TaqMan data were analyzed by the 2(-ΔΔCT) method [31] to determine fold change in gene expression (mock treated cells = 1.00). The ΔCT was taken as the difference between the CD44v or CD44 total and the 18S ribosomal RNA CTs. The ΔΔCT was obtained using the mean ΔCT of mock treated cells as calibrator. Each TaqMan result was compared to 1.00 using 2-tailed paired t-test. Statistical significance was set at p < 0.05.

Results

Calcitonin increases CD44v

In the PC-3M-derived CT-cells, a 50 or 250 μM CT dose after 48 h had little effect on the total amount of CD44 RNA, but the CD44v was tripled (Fig. 1a). Although different binding affinities of primer/probe sets preclude determining CD44v as a percent of CD44 total, the relative percent of CD44v RNA can be calculated by the 2(-ΔΔCT) method, as increasing fivefold after 50 μM CT. The same response, but less marked, was seen in Gsα-QL cells, at 50 and 250 μM doses. In CTR-cells and PC-3 cells – both lacking CTR – exogenous CT had little effect. Similarly, BPH-1 cells responded to CT with very slight stimulatory effect on CD44v, and no effect on CD44 total. At the protein level, however, the CT-cells treated with CT showed increases in both total and variant CD44 after just 3 h (Fig. 1b) and at 48 h (Fig. 1c). The stimulation of CD44v protein was attenuated by cycloheximide up to 9 h after CT (data not shown). This suggests that de novo protein synthesis is required and that upregulation of CD44v is not simply a result of protein stabilization.
Figure 1
Figure 1

1a. RNA response to exogenous CT at 48 h is calcitonin (CT) receptor-dependent. CD44 total and variant RNA are quantified by triplicate TaqMan RT-PCR experiments. In benign BPH-1 cells, no response is observed to exogenous calcitonin (CT). CT-cells, a PC-3M derivative that lack endogenous CT but have CT receptor, showed a decrease in CD44 total RNA but an increase in variant RNA. The Gsα-QL cell derivative showed the same trend. In CT-receptor-negative CTR- and PC-3 cells, there is no significant response to CT. Error bars are standard deviation. *p = 0.01; † p = 0.05 with respect to mock treated controls. 1b. Western blot analysis. Exogenous calcitonin given to the CT-cells for 3 h stimulates expression of CD44s at 75 kD (top), and CD44v at 180 kD and its cleavage products below 97 kD. Comparison is shown to cells with no treatment (NT). β-actin analysis control confirms equal protein loading (bottom). 1c. This stimulatory effect persists at 48 h and at doses of 50 mM or 250 mM exogenous calcitonin. Also, a time-dependent reduction in protein was observed after cycloheximide treatment, suggesting that CT effect on CD44 variant requires de novo protein synthesis and does not result from protein stabilization. 1d. CT+ cells, endogenously expressing CT, are derived from PC-3M cells and have increased RNA for CD44v (p = 0.02) but a decrease in CD44 total (p = 0.008).

In CT+ cells, CD44v mRNA doubled compared to PC-3M while CD44 total expression was cut in half (Fig. 1d). This suggests that endogenous CT exerts an increase on CD44 variant similar to exogenous CT.

Protein kinase A and MAP kinase pathways and their interaction with calcitonin

Gsα-QL cells have high basal levels of CD44v7-10; for this reason, these cells were used to examine the effects of protein kinase A (PKA) and MAPK pathway inhibitors. PKA inhibitor lowered CD44 total and CD44v mRNA (Fig. 2a) and dose-dependently decreased protein for both (Fig. 2b). Downstream to PKA, inhibition of MEK significantly decreased CD44 total (p = 0.001) and non-significantly decreased CD44v. In contrast, inhibition of JNK had no significant effects. p38 inhibitor led to a larger, significant decrease in CD44 variant and a smaller significant decrease in CD44 total (Fig. 2a). MEK and JNK inhibitors were also tested in PC-3 cells and had no effect (data not shown). MEK inhibitor was also tested in BPH-1 cells, in which it reduced CD44 total and variant RNA.
Figure 2
Figure 2

2a. RNA response to molecular inhibitors. CD44 total and variant RNA in triplicate TaqMan RT-PCR experiments. In subconfluent Gsα-QL prostate cancer cells, significant decreases of about 50% or more were observed after protein kinase A (PKA) inhibitor H-89, or inhibitors of downstream signaling pathways MEK or p38 kinase, but not JNK inhibitor. Error bars are standard deviation. *p = 0.01; **p = 0.001; †p = 0.0002; ***p = 0.0001 with respect to mock treated controls. 2b. Western blot analysis. Protein kinase A inhibitor exerts a dose-dependent decrease on CD44s and CD44v compared with EtOH control in Gsα-QL cells.

To examine the dependence of CT effects on MAPK pathways, the CT-cells were pretreated with p38 inhibitor 4 h prior to administration of CT. Results were similar to p38 inhibitor alone: more than 50% decrease in CD44 total but none in CD44v (Fig. 3). This lack of CD44v suppression contrasts with p38 inhibitors marked CD44v suppression in Gsα-QL cells (Fig. 2a), which have far higher CD44v[4]. This suggests that CT mediated splicing is through p38 kinase. In further support of this, the expected CT induced tripling of CD44v mRNA in CT-cells (Fig. 1a) was prevented by p38 inhibitor pretreatment. Pretreatment with MEK inhibitor before CT also blunted the expected rise in CD44 variant mRNA seen in Fig. 1a, and JNK inhibitor pretreatment had no effect (data not shown).
Figure 3
Figure 3

In CT-cells, the blockage of p38 kinase counteracts exogenous calcitonin (CT) stimulatory effect on CD44 variant RNA expression. Triplicate TaqMan RT-PCR experiments. While p38 blockade does not affect the CT-induced decrease in CD44 total, it does abrogate the expected tripling (Fig. 1) in CD44 variant. Conversely, MEK inhibitor moderately reduced total and variant CD44, and this effect was not counteracted by CT, suggesting CT does not act downstream of MEK. *p = 0.02; **p = 0.006 with respect to mock treated controls.

Discussion and conclusion

Here, we demonstrate that calcitonin (CT) causes CT receptor-dependent increases in CD44 alternate splicing in prostate cancer (PC), apparently mediated through p38 kinase. Furthermore, transcription but not splicing appears to require the MEK/ERK (MAPK) pathway. Proposed interactions are shown (Fig. 4).
Figure 4
Figure 4

Proposed effects of calcitonin and MAP kinase pathways on CD44 expression in androgen-independent prostate cancer. Calcitonin (CT) binds to its receptor (CTR), which is coupled to the Gsα transduction protein. Gsα activity, mediated through cAMP, activates protein kinase A (PKA) [19, 25]. PKA activates the MAPK kinase (MEK)-extracellular regulated kinase (ERK) pathway, that facilitates CD44 transcription. CT also induces splicing of CD44 to include v7-10, dependent on p38 but not on PKA. p38 may be induced by Exchange protein activated by cAMP (Epac). p38 could affect splicing machinery directly, through other downstream effectors, or by causing release of intracellular Ca2+.

Paracrine CT is among several growth factors that interact with CD44[22]. In our prior in vitro studies up to 100 nM exogenous CT[6], or CT originating endogenously (in a PC-3 derivative called CT+ [4]), increased CD44v7-10 expression at the mRNA and protein levels. This was also observed in LnCaP, PC-3, and PC-3M derived cells; however, we had not examined total CD44 previously. Here, we used CT-minus (CT-) cells, an androgen-independent PC-3M derivative, to exclude all endogenous CT influence, so any effects would be attributable solely to exogenous CT. In CT-cells, the aberrant splice product is CD44v7-10[6]. This action occurred also in Gsα-QL cells, which are CTR+. Finally, CT+ cells showed an increase in CD44v compared with PC-3M cells. Supporting the view that this stimulation was CT-receptor mediated and not nonspecific, administering CT to CT-receptor negative PC-3 or CTR-cells did not have this effect. In further support of this interpretation, with benign BPH-1 cells, which are also negative for CT and CTR (personal communication, GV Shah), exogenous CT exerted no effect.

It is a novel observation that CT increases CD44v mRNA and protein as early as 3 h in cells that are CTR+, and has little effect on CD44 total. A response to CT should occur in the first several hours (personal communication, GV Shah), and indeed these increases were evident in CD44 protein levels at 3 h and 48 h.

Since the MEK/ERK pathway and the two stress-activated MAPK pathways are implicated in androgen-independent prostate cancer growth[32], we tested all three for modulation of CD44. We had found that CD44v7-10 protein was overexpressed in xenografts of Gsα-QL compared to PC-3M[3]; and in vitro, pharmacologic stimulation of Gsα or adenylyl cyclase raised CD44v7-10[6]. Using a PKA inhibitor, we found reduced total and CD44v7-10 mRNA, suggesting involvement of MEK pathway. Over half of PC cases have activated MEK-ERK signaling, shown by immunohistochemistry for p44/ERK1 and p42/ERK2[33].

To assess MAPK inhibitor effects, we chose Gsα-QL cells, derived from metastasizing PC-3M cells that stably express gsp mutant, constitutively active Gsα [17, 19] because they have high baseline CD44v7-10[3, 6]. We found MEK inhibitor caused similar percent decreases in CD44 total and CD44 variant, implicating MEK in transcription if not CD44v splicing. Similar effects have been noted with ras oncoprotein, which acts on the MEK-ERK pathway[24]. Ras activation can induce CD44 promoter activity in fibroblasts, as shown using transient cotransfection of c-ras expression constructs and CD44 promoter reporter gene constructs[7]. Leakiness of splice control is proposed to lead to increased CD44v[7]. In activated T-lymphocytes during the immune response, mutant ras stimulation of MEK-ERK pathway increases CD44 total mRNA and triggers inclusion of CD44v exons in the mature RNA[24]; from our experiments, MEK seems to be active at least in CD44 transcription in Gsα-QL cells.

Some studies have suggested a positive feedback loop coupling MEK/ERK pathway and CD44v splicing. Activation of ras oncogene in rat fibroblasts[7] and HeLa cervical cancer[23] and of its effector, the MAP kinase pathway in T-cells[24] both upregulate CD44v splicing. CD44 variants, in turn, serve as coreceptors for growth factor receptors that activate ras[23] or form complexes with receptor tyrosine kinases such as c-met[8, 21] to mediate cell signaling. Moreover, CD44v6 promotes T-cell proliferation by persistently activating MAP kinases[20], and CD44v8-10 causes apoptosis resistance in small cell lung cancer by activating Rho-stimulated focal adhesion kinase (FAK)[34].

We examined p38 kinase in benign and PC cells. In BPH-1, CD44 total RNA decreased with p38 kinase inhibition but variant form was unchanged. Since benign prostate lacks the aberrant splicing leading to CD44v7-10[3], but CD44v3-10 expression is present[35], the latter may be the form detected in benign cells. In Gsα-QL cells, a more marked effect on total and variant CD44 was seen. However, p38 may have CT-independent actions. Similar to our current and previous[6] findings with CD44 and Gsα, p38 and MEK (but not JNK) were responsive to G-protein-coupled P2Y purinoceptor agonist ATP in PC-3 cells (CTR-negative), and these 2 pathways were required for invasion[30]. p38 has recently been recognized as a cell proliferation and survival factor in PC[36] partly by regulating IL-6 secretion[32]. Taken together with our findings about the MEK/ERK role in CD44 transcription, this could reflect convergence of the ERK1/2 and p38 systems in activating the MNK1 kinase, which enhances transcription of certain targets[37], suggesting a common final pathway that stimulates CD44 expression in PC.

We tested possible JNK pathway effects on CD44, not previously examined in the literature. JNK appears mainly important in PC apoptosis[29, 38] and promoting chemotherapy susceptibility. JNK inhibitor slightly decreased CD44 total protein and did not change CD44v mRNA or protein in Gsα-QL cells. Our data suggest that JNK is a minor influence on CD44 expression.

Inhibition of p38 and MEK pathways affected CD44 in Gsα-QL cells. To investigate whether either might mediate CT's effects on CD44, we administered CT to CT-cells after blocking either one of these pathways. CT-cells have low baseline CD44v[6], and p38 inhibitor did not suppress the CD44v, but it blocked the expected stimulation of CD44v by CT, suggesting that p38 mediates CT-stimulated alternative splicing. The marked CD44v suppression seen in Gsα-QL cells, which have endogenous CT and high baseline CD44v, adds support for this interpretation. It is tempting to speculate that CT signaling, raising cAMP, may act through the effector, "exchange factor directly activated by cAMP" (Epac, Fig. 4). Epac has been shown to activate p38 kinase and mobilize intracellular calcium in neurons[39]. This PKA-independent mechanism would explain why PKA affected primarily CD44 transcription, yet p38 showed evidence of an additional effect on splicing.

To our knowledge, this is the first report in PC of how interactions between CT, and MAP kinase pathways, dysregulate the expression and splicing of the CD44 molecule. CD44 variant isoforms, probably through alterations in multimerization[12] and ligand binding[4], allow prostate cancer invasion[3, 6]. This knowledge may find application in targeting the aberrant splicing of CD44 in PC by gene therapy, molecular inhibitor therapy, or for sensitization to radiotherapy.

Abbreviations

CD44: 

cell determinant 44

CT: 

calcitonin

CTR: 

calcitonin receptor

ERK: 

extracellular signal-regulated kinase

JNK: 

Jun N-terminal kinase

MAPK: 

mitogen-activated protein kinase

PC: 

prostate cancer

PKA: 

protein kinase A.

Declarations

Acknowledgements

This work was supported by Department of Defense Prostate Cancer Research Program, Grant PC060671 to K.A.I.

Authors’ Affiliations

(1)
From the Department of Pathology, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA

References

  1. Iczkowski KA, Pantazis CG, Collins J: The loss of expression of CD44 standard and variant isoforms is related to prostatic carcinoma development and tumor progression. J Urol Pathol. 1997, 6: 119-129.Google Scholar
  2. Iczkowski KA, Bai S, Pantazis CG: Prostate cancer overexpresses CD44 variants 7–9 at the messenger RNA and protein level. Anticancer Res. 2003, 23: 3129-3140.PubMedGoogle Scholar
  3. Omara-Opyene AL, Qiu J, Shah GV, Iczkowski KA: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest. 2004, 84: 894-907. 10.1038/labinvest.3700112. Editorial Comment: 811–813.View ArticlePubMedGoogle Scholar
  4. Iczkowski KA, Omara-Opyene AL, Shah GV: The predominant CD44 splice variant in prostate cancer binds fibronectin, and calcitonin stimulates its expression. Anticancer Res. 2006, 26: 2863-2872.PubMedGoogle Scholar
  5. Miyake H, Hara I, Okamoto I, Gohji K, Yamanaka K, Arakawa S, Saya H, Kamidono S: Interaction between CD44 and hyaluronic acid regulates human prostate cancer development. J Urol. 1998, 160: 1562-1566. 10.1016/S0022-5347(01)62613-2.View ArticlePubMedGoogle Scholar
  6. Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV: Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res. 2005, 25: 2075-2083.PubMedGoogle Scholar
  7. Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, Zoller M, Lichtner RB, Herrlich P, Ponta H: A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res. 1993, 53: 1516-1521.PubMedGoogle Scholar
  8. Jothy S: CD44 and its partners in metastasis. Clin Exp Metastasis. 2003, 20: 195-201. 10.1023/A:1022931016285.View ArticlePubMedGoogle Scholar
  9. Vis AN, van Rhijn BW, Noordzij MA, Schroder FH, Kwast van der TH: Value of tissue markers p27(kip1), MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol. 2002, 197: 148-154. 10.1002/path.1084.View ArticlePubMedGoogle Scholar
  10. Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, Kwast van der TH: Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol. 2000, 164: 2156-2161. 10.1016/S0022-5347(05)66989-3.View ArticlePubMedGoogle Scholar
  11. Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS: CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol. 2007, 31: 1119-1126.PubMedGoogle Scholar
  12. Lesley J, Kincade PW, Hyman R: Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur J Immunol. 1993, 23: 1902-1909. 10.1002/eji.1830230826.View ArticlePubMedGoogle Scholar
  13. Shah GV, Noble MJ, Austenfeld M, Weigel J, Deftos LJ, Mebust WK: Presence of calcitonin-like immunoreactivity in human prostate gland: evidence for iCT secretion by cultured prostate cells. Prostate. 2007, 21: 87-97. 10.1002/pros.2990210202.View ArticleGoogle Scholar
  14. Chien J, Ren Y, Qing Wang Y, Bordelon W, Thompson E, Davis R, Rayford W, Shah G: Calcitonin is a prostate epithelium-derived growth stimulatory peptide. Mol Cell Endocrinol. 2001, 181: 69-79. 10.1016/S0303-7207(01)00530-5.View ArticlePubMedGoogle Scholar
  15. Shah GV, Rayford W, Noble MJ, Austenfeld M, Weigel J, Vamos S, Mebust WK: Calcitonin stimulates growth of human prostate cancer cells through receptor-mediated increase in cyclic adenosine 3',5'-monophosphates and cytoplasmic Ca2+ transients. Endocrinology. 1994, 134: 596-602. 10.1210/en.134.2.596.PubMedGoogle Scholar
  16. Sabbisetti VS, Chirugupati S, Thomas S, Vaidya KS, Reardon D, Chiriva-Internati M, Iczkowski KA, Shah GV: Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer. 2005, 117: 551-560. 10.1002/ijc.21158.View ArticlePubMedGoogle Scholar
  17. Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG, Shah GV: Constitutive activation of stimulatory guanine nucleotide binding protein (Gsalpha-QL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene. 1999, 18: 3376-3382. 10.1038/sj.onc.1202690.View ArticlePubMedGoogle Scholar
  18. Thomas S, Muralidharan A, Shah GV: Knock-down of calcitonin receptor expression induces apoptosis and growth arrest of prostate cancer cells. Int J Oncol. 2007, 31: 1425-1437.PubMedGoogle Scholar
  19. Chien J, Shah GV: Role of stimulatory guanine nucleotide binding protein (Gsalpha) in proliferation of PC-3M prostate cancer cells. Int J Cancer. 2001, 91: 46-54. 10.1002/1097-0215(20010101)91:1<46::AID-IJC1008>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
  20. Marhaba R, Bourouba M, Zoller M: CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal. 2005, 17: 961-973. 10.1016/j.cellsig.2004.11.017.View ArticlePubMedGoogle Scholar
  21. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16: 3074-3086. 10.1101/gad.242602.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Ponta H, Sherman L, Herrlich PA: CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol. 2003, 4: 33-45. 10.1038/nrm1004.View ArticlePubMedGoogle Scholar
  23. Cheng C, Yaffe MB, Sharp PA: A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev. 2006, 20: 1715-1720. 10.1101/gad.1430906.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Weg-Remers S, Ponta H, Herrlich P, Konig H: Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 2001, 20: 4194-4203. 10.1093/emboj/20.15.4194.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Thomas S, Chigurupati S, Anbalagan M, Shah G: Calcitonin increases tumorigenicity of prostate cancer cells: evidence for the role of protein kinase A and urokinase-type plasminogen receptor. Mol Endocrinol. 2006, 20: 1894-1911. 10.1210/me.2005-0284.View ArticlePubMedGoogle Scholar
  26. Forster-Horváth C, Bocsi J, Rásó E, Orbán TI, Olah E, Tímár J, Ladányi A: Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes. Eur J Immunol. 2001, 31: 600-608. 10.1002/1521-4141(200102)31:2<600::AID-IMMU600>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
  27. Leemhuis J, Boutillier S, Schmidt G, Meyer DK: The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J Pharmacol Exp Ther. 2002, 300: 1000-1007. 10.1124/jpet.300.3.1000.View ArticlePubMedGoogle Scholar
  28. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, Hong WK: Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res. 2005, 11: 6065-6074. 10.1158/1078-0432.CCR-05-0009.View ArticlePubMedGoogle Scholar
  29. Davoodpour P, Landstrom M: 2-Methoxyestradiol-induced apoptosis in prostate cancer cells requires Smad7. J Biol Chem. 2005, 280: 14773-14779. 10.1074/jbc.M414470200.View ArticlePubMedGoogle Scholar
  30. Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF, Fang WG: ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 2004, 215: 239-247. 10.1016/j.canlet.2004.05.023.View ArticlePubMedGoogle Scholar
  31. Livak KL, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔCT) method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
  32. Shida Y, Igawa T, Hakariya T, Sakai H, Kanetake H: p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem Biophys Res Commun. 2007, 353: 744-749. 10.1016/j.bbrc.2006.12.077.View ArticlePubMedGoogle Scholar
  33. Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, Hartmann A, Stoehr R: Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol. 2006, 50: 1102-1109. 10.1016/j.eururo.2005.11.031.View ArticlePubMedGoogle Scholar
  34. Fujita Y, Kitagawa M, Nakamura S, Azuma K, Ishii G, Higashi M, Kishi H, Hiwasa T, Koda K, Nakajima N, Harigaya K: CD44 signaling through focal adhesion kinase and its anti-apoptotic effect. FEBS Lett. 2002, 528: 101-118. 10.1016/S0014-5793(02)03262-3.View ArticlePubMedGoogle Scholar
  35. Harrison GM, Davies G, Martin TA, Mason MD, Jiang WG: The influence of CD44v3–v10 on adhesion, invasion and MMP-14 expression in prostate cancer cells. Oncol Rep. 2006, 15: 199-206.PubMedGoogle Scholar
  36. Ricote M, Garcia-Tunon I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M: The p38 transduction pathway in prostatic neoplasia. J Pathol. 2006, 208: 401-407. 10.1002/path.1910.View ArticlePubMedGoogle Scholar
  37. Raught B, Gingras AC: eIF4E activity is regulated at multiple levels. Int J Biochem Cell Biol. 1999, 31: 43-57. 10.1016/S1357-2725(98)00131-9.View ArticlePubMedGoogle Scholar
  38. Cho SD, Ahn NS, Jung JW, Yang SR, Park JS, Lee YS, Jo EH, Hwang JW, Lii J, Kang KS: Critical role of the c-JunNH2-terminal kinase and p38 mitogen-activated protein kinase pathways on sodium butyrate-induced apoptosis in DU145 human prostate cancer cells. Eur J Cancer Prev. 2006, 15: 57-63. 10.1097/01.cej.0000195704.05246.fc.View ArticlePubMedGoogle Scholar
  39. Ster J, De Bock F, Guerineau NC, Janossy A, Barrere-Lemaire S, Bos JL, Bockaert J, Fagni L: Exchange protein activated by cAMP (Epac) mediates cAMP activation of p38 MAPK and modulation of Ca2+-dependent channels in cerebellar neurons. Proc Natl Acad Sci USA. 2007, 104: 2519-2524. 10.1073/pnas.0611031104.View ArticlePubMedPubMed CentralGoogle Scholar

    40. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/260/prepub

Copyright

© Robbins et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us